Epilog has introduced the routine use of their Epilog PreOp service for the analysis of long-term EEG data recorded in patients with refractory epilepsy at Yale New Haven Hospital (YNHH) and the Yale Comprehensive Epilepsy Center (YCEC). The first steps were taken at the Annual Meeting of the American Epilepsy Society meeting in Houston in December 2016 – just six months after Epilog had launched in Europe. After a thorough internal evaluation of Epilog PreOp, YNHH has now decided to implement Epilog PreOp as one of the key assessments used in the pre-surgical evaluation of patients with medically refractory epilepsy.
“We are thrilled to partner with Yale New Haven Hospital/Yale Comprehensive Epilepsy Center and showcase our FDA approved product in one of the leading epilepsy centers in the US,” explains Dr Strobbe, co-CEO of Epilog. “Their passion and dedication to improve epilepsy patients’ quality of life is well known and we share this mission. It’s been a marvelous experience working closely together with Rebecca Khozein, Program Director of Neurophysiology. For the full Epilog team, it’s an honor to continue the collaboration with the Yale epilepsy experts.”
The Comprehensive Epilepsy Center at Yale University is internationally renowned for innovative research and clinical excellence. Its multidisciplinary program leads the way in the treatment of epilepsy. With Epilog PreOp, a cloud-based service for 3D Electrical Source Imaging (ESI), YNHH has now another state-of-the-art tool at hand to determine which region in the brain is causing the epilepsy.
A great advantage of Epilog’s service is that Centers are able to get reimbursed by most US payers for the professional component of this EEG diagnostic technology, allowing state-of-the-art technology to find its way faster to the patient.
